Brucke Financial Inc. Purchases New Shares in argenx SE (NASDAQ:ARGX)

Brucke Financial Inc. acquired a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 629 shares of the company's stock, valued at approximately $412,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Point72 Europe London LLP acquired a new position in argenx during the fourth quarter valued at approximately $5,839,000. Stephens Inc. AR bought a new position in shares of argenx in the 4th quarter valued at $310,000. Jones Financial Companies Lllp raised its holdings in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of argenx by 10.0% during the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after buying an additional 639 shares during the last quarter. Finally, Atomi Financial Group Inc. acquired a new stake in argenx in the fourth quarter valued at about $339,000. Institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

ARGX has been the subject of several research analyst reports. JMP Securities set a $699.00 target price on argenx in a research note on Wednesday, May 14th. Oppenheimer upped their price objective on shares of argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Citigroup reissued a "buy" rating on shares of argenx in a research note on Wednesday, May 21st. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Finally, Baird R W upgraded shares of argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $709.18.

argenx Stock Performance

Shares of NASDAQ ARGX traded down $4.21 during midday trading on Friday, reaching $576.74. The stock had a trading volume of 350,163 shares, compared to its average volume of 323,511. The company's 50 day moving average price is $586.57 and its 200 day moving average price is $612.43. argenx SE has a twelve month low of $361.26 and a twelve month high of $678.21. The firm has a market cap of $35.22 billion, a price-to-earnings ratio of -655.39 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million. Equities analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.